[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemoperfusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemoperfusion":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100442670",false,"NCT05044403","Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.","Clinical Impact of Hemoperfusion With a Neutral Macroporous Resin Cartridge as Adjunctive Treatment in Septic Patients With Multiorgan Dysfunction Syndrome (MODS) Admitted to Intensive Care Units.","Inclusion Criteria:\n\n* Patients with a sepsis diagnosis, according to the diagnostic criteria of the International Sepsis-3 Consensus Conference, and without response to the treatment of septic shock who meet the following conditions:\n* Sepsis of abdominal origin with controlled infectious focus.\n* Noradrenaline dose\\> 0.5 µg \u002F kg \u002F min to maintain adequate organ perfusion after optimization of fluid therapy.\n* Dysfunction of two or more organs with SOFA ≥ 9 (5).\n* Blood lactate ≥ 2 mmol \u002F L.\n* Procalcitonin (PCT)\\> 10 ng \u002F mL.\n* CRP\\> 100 mg \u002F L.\n* IL-6\\> 2000 pg \u002F ml.\n\nExclusion Criteria:\n\n* Age under 18 years or over 80 years.\n* Pregnancy or breastfeeding.\n* Terminally ill patients or with a life expectancy of less than 48 hours.\n* Thrombocytopenia \\\u003C60,000 \u002F mm3.\n* Pancytopenia.\n* Severe coagulopathy with high risk of bleeding.\n* Inclusion in another research protocol.\n* In case of re-entry during the study period, only the first admission will be included.\n* Use of another haemoperfusion device.","ALL","18 Years","80 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"NA","Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.",[26,27,28],"Hemoperfusion","Multiorgan Failure","Sepsis","RECRUITING","2025-06-04",{"date":32,"type":33},"2025-06-10","ACTUAL",{"date":35,"type":33},"2023-03-01",{"date":37,"type":20},"2025-12-20",{"name":39,"class":40},"Hospital Clinic of Barcelona","OTHER",""]